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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S47532.3). A signiﬁcant positive interaction was found between severe pain
at baseline and treatment effect (interaction coefﬁcient 13.6, 95%CI 1.4-
25.8). A non-signiﬁcant overall interaction estimate was found for
inﬂammatory signs 12.5 (95%CI -7.22-32.3). However, a strongly pos-
itive interaction estimate (45.3, 95%CI 24.4-66.1) was found for
inﬂammation and treatment effect when analyzed in the studies where
inﬂammation was measured by ultrasound.
Conclusions: Our results show that patients with severe pain at base-
line do beneﬁt signiﬁcantly more from IA glucocorticoid injections than
those with less severe pain and this could be used as a predictive
measure of response in clinical practice. However inﬂammation deﬁned
by ultrasound provided an even more signiﬁcant measure of a positive
treatment response of IA glucocorticoids in patients with knee or hip
OA. The differences in treatment response at short-term follow-up
between IA glucocorticoid treatment and IA placebo were much larger
when inﬂammatory signs, measured by ultrasound, were present
compared to absence of inﬂammatory signs.
867
BONE MARROW LESIONS MAY NOT RESPOND TO ANTI-
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Purpose: Intra-articular steroid therapy to the knee is associated with a
reduction in pain in patients with symptomatic knee OA. The mecha-
nism by which treatment is linked with a reduction in pain is unknown
though thought in part to be related to a reduction in synovitis. Bone
marrow lesions (BMLs) are poorly circumscribed lesions of water signal
on MRI using fat suppressed pulse sequences; while BMLs may be
caused by mechanical stress across the joint, their relation to inﬂam-
mation is unknown though it is possible they may be a candidate target
for steroid therapy as they are linked with knee pain and ﬂuctuate over
time. The aim of this analysis was to determine whether intra-articular
steroid therapy is associated with a change in BMLs.
Methods: Men and women aged 40 years and older with painful knee
OA, and who met American College of Rheumatology criteria for the
disease, were recruited for participation in an ongoing open label
clinical trial of intra-articular steroid therapy. Subjects who took part in
the study had signiﬁcant knee pain and knee OA of grade 2 (Kellgren-
Lawrence) or higher. At baseline they completed also the Knee Injury
and Osteoarthritis Outcome Score (KOOS). They had a Gadolinium(Gd)-
enhanced MRI immediately prior to having an intra-articular steroid
injection with repeat questionnaire and Gd-enhanced MRI scan at the
post-injection visit usually within a 2 week period. Response was
determined using the OARSI responder criteria. Those who responded
were followed up by serial telephone call until their knee pain recurred
or at 6 months at which point a further Gd-enhanced MRI was sched-
uled. The knee images were assessed semi-quantitatively for BML
severity (score 0-45 using the WORMS method) at all three time points
by an experiencedMSK radiologist. Synovial tissue volumewas assessed
using manual segmentation and computer image analysis of the con-
trast enhanced images. We looked at mean change in BML severity
score, between baseline and post-injection visit, and themean change in
BML score between baseline and the ﬁnal scan.We looked also at change
in synovial volume between baseline and the post injection scan.
Results: 100 patients with imaging data were included in this analysis.
Their median age was 62.0 years (SD 10.4 years), and 48 were female.
The median time between baseline and post-injection scan was 8 days
(IQR 7 to 14 days). Among those who responded (67) pain recurred
within 6 months in 46. The median BML score at baseline was 8.0 (IQR
4.0 to 12.0), post-injection visit 8.0 (IQR 4.2 to 12.0) and 7 (IQR 4.0 to
10.9) at ﬁnal visit. The score did not differ between the baseline and
post-injection scan (mean within person difference ¼ 0.05 points; 95%
CI -0.21 to 0.31 points; p ¼ 0.72) however a slight difference was noted
between the baseline and ﬁnal scan (mean within person difference ¼
-0.36 points; 95% CI -0.67 to -0.06 points; p ¼ 0.02). This within-person
difference reﬂects a reduction of 4.6% in the baseline BML score, which,
while statistically signiﬁcant, is a clinically small change. In contrast,
synovial volume shrank between the baseline and post-injection visit
(mean within person difference ¼ -1082mm3; 95% CI -1996 to
-168mm3; p ¼ 0.02). This within-person difference reﬂects a reduction
of 13.2% in the baseline synovitis score.Conclusions: BMLs show little change in response to intra-articular
steroid therapy in patients with symptomatic knee OA, suggesting they
may not respond to anti-inﬂammatory treatments.
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Purpose: Salmon calcitonin (sCT) has been shown to exert beneﬁcial
metabolic actions on cartilage and bone turnover and may therefore be
useful in the management of osteoarthritis (OA). A calcitonin-based oral
treatment for knee OA recently failed to meet the primary endpoint for
efﬁcacy in a two-year placebo-controlled clinical trial, though demon-
strating positive effects on pain and function. The objective of our
project is to synthesize a new polymeric conjugate between hyaluronic
acid (HA) and salmon calcitonin and to evaluate its potential as intra-
articular treatment for OA. The rationale is to retain sCT in the joint
cavity, thus maximizing and prolonging the local activity and avoiding
the side effects related to a systemic administration.
Methods: HA was linked to sCT by means of a spacer having pendant
aldehyde groups for selective conjugation at the N-terminus of the
peptide.
The residual activity of conjugated sCT was investigated in rats by
measuring the plasma calcium level after i.v. injection. Preliminary PK
studies were performed by labeling HA-sCT and sCT with a ﬂuorescent
dye for the detection in blood samples after i.a. injection. In addition,
blood samples were withdrawn at ﬁxed times up to 24 hours and the
total calcium levels were measured using a colorimetric calcium assay.
Unilateral OA was surgically induced in the rabbit knees by anterior
cruciate ligament transection (ACLT). Controls (PBS and HA), sCT and
HA-sCT at 25, 100 and 400 UI, were administered by i.a. injection once a
week at day 10, 17 and 24 post-surgery. The efﬁcacy was evaluated by
macroscopic examination of the treated joint, histopathological
assessment of the synovial membrane and of the femoral condyles. The
histopathological criteria score was based on the evaluation of four
parameters: articular cartilage morphology, subchondral bone mor-
phology, cartilage thickness, and arrangement of chondrocytes.
Results: The new HA-sCT conjugate was synthesized according to a
patented technology that avoids the formation of heterogeneous and
cross-linked products.
The potency of the conjugated sCT was evaluated by i.v. injection,
showing that it maintains a comparable potency with respect to the free
protein and sustains the hypocalcaemic action for a longer time.
Interestingly, after local administration, unlike free sCT, HA-sCT did not
cause a systemic reduction of calcium concentration, suggesting a
negligible extra-articular diffusion of the conjugated peptide.
The PK study with labelled sCTconﬁrmed this encouraging result: while
i.a. injection of HA-sCT led to very low and constant plasma peptide
concentration, the local administration of free sCT resulted in high
ﬂuorescence in plasma, demonstrating a fast clearance of the peptide
